Eunomia Pharma Services
All resources

Reference · Updated 30 September 2026

PMCPA case library

One-line summaries of 21 recent completed PMCPA cases, with the clauses ruled in breach. Each links to the full case report on the PMCPA website, which is the authoritative record.

CaseCompanyCompletedTopicClauses in breach
CASE/0900/03/26 & CASE/0915/03/26
2024 Code		GSK27 Aug 2026Facebook adverts for an HCP webinar alleged to reach the publicNo breach
CASE/0829/12/25
2024 Code		Chiesi20 Aug 2026LinkedIn post and press releaseNo breach
CASE/0842/01/26
2024 Code		Britannia11 Aug 2026Webinar5.1
CASE/0747/09/25
2024 Code		Roche5 Aug 2026Relative risk presented without absolute risk6.1
CASE/1000/06/26
2024 Code		Ferring3 Aug 2026Employee LinkedIn job advert describing an unlicensed medicine (abridged procedure)3.1, 5.2
CASE/0874/02/26
2024 Code		GSK28 Jul 2026Incomplete responses to the PMCPA in an earlier case (public reprimand)2, 5.1
CASE/0749/09/25
2024 Code		Neuraxpharm6 Jul 2026Symposium content (complaint by Roche)5.1, 6.1
CASE/0685/08/25
2024 Code		Eli Lilly3 Jul 2026News coverage of Phase 3 results from a press release (appeal)2, 3.1, 5.1
CASE/0999/06/26
2024 Code		Sanofi2 Jul 2026Disease-education video used after certification lapsed, after personnel left without the material being reassigned (voluntary admission)8.5
CASE/0784/10/25
2024 Code		Novo Nordisk30 Jun 2026Sponsorship not clearly declared on conference materials5.6
CASE/0812/11/25
2024 Code		AstraZeneca24 Jun 2026Company-funded therapy review serviceNo breach
CASE/0719/09/25
2024 Code		AGB Pharma22 Jun 2026Prescribing information omitted SmPC warnings2, 5.1, 6.1, 12.1
CASE/0688/08/25
2024 Code		Sanofi17 Jun 2026Global press release comparing hospitalisation data (complaint by Pfizer)2, 5.1, 6.1, 6.2, 6.6, 26.1, 26.2
CASE/0748/09/25
2024 Code		Ipsen15 May 2026Company content in a doctors’ network email newsletter3.6, 15.6
CASE/0838/12/25
2024 Code		Pfizer15 May 2026Company content in a doctors’ network email newsletter3.6, 15.6
CASE/0724/09/25
2024 Code		Eli Lilly11 May 2026Newspaper interview about an unlicensed medicine3.1, 5.1
CASE/0722/09/25
2024 Code		IBSA22 Apr 2026Websites accessible to the public5.1, 26.1
CASE/0409/12/24
2021 Code		Alnylam21 Apr 2026Congress booth, tutorials and evening meeting (complaint by Pfizer; Clause 2 overturned on appeal)5.1, 11.2
CASE/0686/08/25
2024 Code		AstraZeneca9 Apr 2026Senior leader’s LinkedIn post linking to an article naming a medicine5.1, 26.1
CASE/0641/06/25
2024 Code		Fresenius Kabi31 Mar 2026ePoster for an unlicensed medicine3.1, 5.1, 11.1
CASE/0303/09/24
2021 Code		Theramex26 Feb 2026Compliance culture, prescribing information and non-interventional study certification2, 4.7, 5.1, 8.3, 12.1

Summaries of published PMCPA case reports, checked 30 September 2026. Read the full report for each case; this is not legal advice. See lessons from recent PMCPA cases.

Questions, answered

Common questions

Where are PMCPA cases published?

On the PMCPA website, which publishes completed cases under the ABPI Code of Practice with the rulings and any sanctions.

What themes appear in recent cases?

In our sample, social media (including employees’ own posts), press releases, certification, prescribing information and whether company involvement was made clear. Our article on lessons from recent PMCPA cases covers them in detail.